

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 April 2011 (14.04.2011)

PCT

(10) International Publication Number
WO 2011/042529 A1

(51) International Patent Classification:
C07D 487/04 (2006.01)

(21) International Application Number:
PCT/EP2010/065077

(22) International Filing Date:
8 October 2010 (08.10.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0917611.6 8 October 2009 (08.10.2009) GB
61/250,892 13 October 2009 (13.10.2009) US

(71) Applicant (for all designated States except US): **GE HEALTHCARE LIMITED** [GB/GB]; Pollards Wood, Nightingales Lane, Chalfont St giles Buckinghamshire HP8 4SP (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WOODCRAFT, John** [US/GB]; GE Healthcare Limited, The Grove Centre, White Lion Road, Amersham Buckinghamshire HP7 9LL (GB). **JONES, Clare** [GB/GB]; GE Healthcare Limited, White Lion Road, Amersham Buckinghamshire HP7 9LL (GB). **GAETA, Alessandra** [IT/GB]; GE Healthcare Limited, White Lion Road, Amersham Buckinghamshire HP7 9LL (GB). **TRIGG, William** [GB/GB]; GE Healthcare Limited, White Lion Road, Amersham Buckinghamshire HP7 9LL (GB). **JONES, Paul** [GB/GB]; GE Healthcare Limited, White Lion Road, Amersham Buckinghamshire HP7 9LL (GB). **PLANT, Stuart** [GB/GB]; GE Healthcare Limited, White Lion Road, Amersham

Buckinghamshire HP7 9LL (GB). **JACKSON, Alexander** [GB/GB]; GE Healthcare Limited, White Lion Road, Amersham Buckinghamshire HP7 9LL (GB).

(74) Agent: **BANNAN, Sally**; GE Healthcare Limited, Pollards Wood, Nightingales Lane, Chalfont St Giles Buckinghamshire HP8 4SP (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: AUTOMATED RADIOSYNTHESIS

(57) Abstract: The present invention provides a method to obtain radiofluorinated compounds useful for in vivo imaging GABA_A receptors. The method of the invention is high-yielding and may conveniently be carried out on an automated synthesizer such as Fastlab™. A further aspect of the invention is a cassette suitable for carrying out the automated method of synthesis of the invention. Novel precursor compounds useful in the method of the invention are also provided, as are a number of novel compounds obtained by the method of the invention.



WO 2011/042529 A1

AUTOMATED RADIOSYNTHESIS

Technical Field of the Invention

The present invention relates to *in vivo* imaging and in particular to *in vivo* imaging of gamma-aminobutyric acid (GABA) receptors of the central nervous system (CNS). The invention provides a method suitable for the automated
5 synthesis of radiofluorinated GABA receptor antagonist compounds.

Description of Related Art


Gamma-aminobutyric acid (GABA) is the most important inhibitory neurotransmitter in the human brain. GABA receptors are transmembrane
10 receptors and fall into two main types, GABA_A receptors and GABA_B receptors. GABA_A receptors have been the major focus of pharmacological development to date. Many GABA_A receptor subtypes have been discovered and novel chemical structures have been developed which are selective for these subtypes. Normal activation of the GABA_A receptor results in chloride ion
15 being selectively conducted through its pore. This chloride channel gating is generally inhibitory on a neuron by virtue of stabilising the membrane potential near to resting level.

Defective GABA_A receptor neurotransmission may be caused by a reduction in GABA_A receptors, or by defective functioning of the GABA_A receptor due to e.g.
20 a genetic mutation in a GABA_A receptor gene, traumatic brain injury, or a pharmacological insult, and is implicated in a number of neurological and psychiatric disorders, including epilepsy, anxiety disorders, Parkinson's disease and chronic pain. The development of radioligands selective for the GABA_A receptor is therefore of value in terms of brain imaging studies in living
25 human patients, in particular those suffering from disorders associated with defective GABA_A receptor neurotransmission.

Flumazenil (also known as flumazepil, code name Ro 15-1788, trade names Anexate, Lanexat, Mazicon, Romazicon) is an imidazo[1,5-

a)[1,4]benzodiazepine that is a neutralising allosteric modulator of GABA_A receptors in the CNS (Johnston 1996 Pharmacol Ther; 69(3): 173-198). The most common use of flumazenil to date has been as an antidote to benzodiazepine overdose as it reverses the effects of benzodiazepines by competitive inhibition at the benzodiazepine binding site of the GABA_A receptor. In addition, because flumazenil has little or no agonist activity, radiolabelled versions thereof have been developed as positron emission tomography (PET) radiotracers.

[¹⁸F]FMZ has the same chemical formula as flumazenil but wherein ¹⁸F is incorporated by direct radiofluorination of a nitro precursor:



[¹⁸F]FMZ binds to the GABA_A receptor with high affinity (K_i around 0.5nM) and selectivity. Ryzhikov *et al* (2005 Nuc Med Biol; 32: 109-116) describe the preparation of [¹⁸F]FMZ from a nitro precursor compound. This synthesis, however, has been found by the present inventors to have a less than optimal end of synthesis (EOS) yield of 2.7-7.7% (described herein as a comparative example). These EOS yields are comparable to those reported by Odano *et al* (Neuroimage 2009; 45(3): 891-902).

The present invention seeks means to obtain radiofluorinated agents that bind to the GABA_A receptor with high affinity in improved yields compared to the prior art methods.


Summary of the Invention

The present invention provides a method to obtain radiofluorinated compounds useful for *in vivo* imaging GABA_A receptors. The method of the invention is

high-yielding in comparison to the prior art methods. A further aspect of the invention is a cassette suitable for carrying out the automated method of synthesis of the invention. Novel precursor compounds useful in the method of the invention are also provided, as are certain novel radiofluorinated
 5 compounds obtained by the method of the invention.

Detailed Description of the Invention

In one aspect, the present invention provides a method to obtain a compound of Formula I:




10 wherein:

one of R^1 and R^2 is ^{18}F and the other is hydrogen; and,

R^3 is a C_{3-5} heterocycle; or, R^3 is $\text{C}(=\text{O})\text{-O-R}^4$ wherein R^4 is hydrogen, or a straight- or branched-chain C_{1-4} alkyl;

wherein said method comprises:

15 (i) providing a precursor compound of Formula Ia:



wherein:

one of R¹¹ and R¹² is a leaving group and the other is hydrogen, wherein:

when R¹¹ is said leaving group it is selected from tri-C₁₋₃ alkyl ammonium or -I⁺-Ar, wherein Ar is phenyl substituted with one or more R* groups, wherein R* is selected from hydrogen, nitro, cyano, halogen, C₁₋₁₀ hydroxyalkyl, C₂₋₁₀ carboxyalkyl, C₁₋₁₀ alkyl, C₂₋₁₀ alkoxyalkyl, C₁₋₁₀ hydroxyalkyl, C₁₋₁₀ aminoalkyl, C₁₋₁₀ haloalkyl, C₆₋₁₄ aryl, C₃₋₁₂ heteroaryl, C₃₋₂₀ alkylaryl, C₂₋₁₀ alkenyl, and C₂₋₁₀ alkynyl; and,

when R¹² is said leaving group it is selected from nitro, tri-C₁₋₃ alkyl ammonium or -I⁺-Ar, wherein Ar is as defined above for R¹¹; and,

10 R¹³ is as defined for R³ of Formula I; and,

(ii) reacting said precursor compound with a suitable source of [¹⁸F]Fluoride.

A "precursor compound" comprises a non-radioactive derivative of a radiolabelled compound, designed so that chemical reaction with a convenient chemical form of the detectable label occurs site-specifically; can be conducted
15 in the minimum number of steps (ideally a single step); and without the need for significant purification (ideally no further purification), to give the desired *in vivo* imaging agent. Such precursor compounds are synthetic and can conveniently be obtained in good chemical purity. The precursor compound may optionally comprise a protecting group for certain functional groups of the
20 precursor compound.

A "leaving group" is a substituent of the precursor compound as defined above which is replaced with ¹⁸F when the precursor compound is reacted with a suitable source of [¹⁸F]fluoride, thereby permitting incorporation of ¹⁸F site-specifically to result in the desired radiofluorinated compound of Formula I.

25 By the term "protecting group" is meant a group which inhibits or suppresses undesirable chemical reactions, but which is designed to be sufficiently reactive that it may be cleaved from the functional group in question under mild enough conditions that do not modify the rest of the molecule. After

deprotection the desired product is obtained. Protecting groups are well known to those skilled in the art and are suitably chosen from, for amine groups: Boc (where Boc is *tert*-butyloxycarbonyl), Fmoc (where Fmoc is fluorenylmethoxycarbonyl), trifluoroacetyl, allyloxycarbonyl, Dde [i.e. 1-(4,4-
5 dimethyl-2,6-dioxocyclohexylidene)ethyl] or Npys (i.e. 3-nitro-2-pyridine sulfenyl); and for carboxyl groups: methyl ester, *tert*-butyl ester or benzyl ester. For hydroxyl groups, suitable protecting groups are: methyl, ethyl or *tert*-butyl; alkoxymethyl or alkoxyethyl; benzyl; acetyl; benzoyl; trityl (Trt) or trialkylsilyl such as tetrabutyltrimethylsilyl. The use of further protecting groups are
10 described in 'Protective Groups in Organic Synthesis', Theodor W. Greene and Peter G. M. Wuts, (Third Edition, John Wiley & Sons, 1999).

The term "alkyl" used either alone or as part of another group is defined herein as any straight, branched or cyclic, saturated or unsaturated C_nH_{2n+1} group.

The term "aryl" used either alone or as part of another group is defined herein
15 as any C_{6-14} molecular fragment or group which is derived from a monocyclic or polycyclic aromatic hydrocarbon, or a monocyclic or polycyclic heteroaromatic hydrocarbon.

The term "halogen" means a group selected from fluorine, chlorine, bromine, and iodine.

20 The term "nitro" refers to the group $-NO_2$.

The term "cyano" refers to the group $-CN$.

The term "carboxyalkyl" refers to an alkyl group as defined above substituted with at least one $-COOH$.

The term "alkoxyalkyl" refers to an alkyl ether radical wherein the term alkyl is
25 as defined above.

The term "hydroxyalkyl" refers to an alkyl radical as defined above wherein at least one hydrogen atom has been replaced by an $-OH$ group.

The term "aminoalkyl" refers to an alkyl radical as defined above wherein at least one hydrogen atom has been replaced by an -NH₂ group.

The term "haloalkyl" refers to an alkyl radical as defined above wherein at least one hydrogen atom has been replaced by a halogen wherein halogen is as
5 defined herein.

The term "heteroaryl" refers to an aryl as defined above wherein at least one carbon atom is replaced with a heteroatom selected from O, N and S.

The term "alkylaryl" refers to an alkyl radical as defined above in which at least one hydrogen atom is replaced by an aryl radical as defined above.

10 The term "heterocycle" refers herein to an aliphatic or aromatic cyclic radical wherein the cycle comprises one or more heteroatoms selected from nitrogen, oxygen or sulfur.

The term "alkenyl" means a straight-chain or branched-chain hydrocarbon radical having one or more double bonds.

15 The term "alkynyl" means a straight-chain or branched chain hydrocarbon radical having one or more triple bonds.


In a preferred embodiment of the method of the invention where R¹ is ¹⁸F, R¹¹ is trimethyl ammonium or -I⁺-Ar.

In a most preferred embodiment of the method of the invention R² is ¹⁸F. When R²
20 is ¹⁸F, it is preferred that R¹² is nitro, trimethyl ammonium or -I⁺-Ar. When R² is ¹⁸F, it is most preferred that R¹² is nitro.


R³ of Formula I and R¹³ of Formula Ia are the same and are preferably C(=O)-O-R⁴, wherein R⁴ is straight or branched-chain C₁₋₄ alkyl, preferably methyl, ethyl, isopropyl or *tert*-butyl. R⁴ is most preferably ethyl, isopropyl or *tert*-butyl, and
25 especially preferably ethyl.

The reaction scheme disclosed by Yang *et al* (2009 Synthesis; 6: 1036-1040)

can be adapted to obtain precursor compounds of Formula Ia wherein R¹¹ is a leaving group. Scheme 1 illustrates how the precursor compounds can be obtained:



- 5 In Scheme 1, where R¹¹ is trialkylammonium, R²¹ is NO₂, and where R¹¹ is an iodonium salt, R²¹ is bromine. R¹³ is as defined for Formula Ia. The appropriate amino benzoic acid compound **a**, equipped to perform the required chemistry to introduce the desired leaving group at later stage, is reacted with triphosgene to afford the benzoxazine-2,4-dione intermediate **b**. Reaction of **b**
- 10 with sarcosine in DMSO yields the benzodiazepine **c**. At this stage, where R¹¹ is trialkylammonium, R²¹ of compound **c** is converted to trialkylammonium in step (i) before carrying out step (ii) to obtain compound **d**. Where R¹¹ is an iodonium salt, R²¹ is converted to the iodonium salt in step (iii) after carrying out step (ii).
- 15 Where R¹² is the leaving group, Scheme 2 may be used to obtain the precursor compound:



R^{22} is as defined for R^{21} in Scheme 1 above. Compound **e** is obtained from commercially-available 2,6-dinitro benzoic acid starting material by standard chemical transformations. Compound **e** is treated as described for compound **a** of Scheme 1 to give the benzodiazepine intermediate **g**, which in turn is transformed in the desired imidazobenzodiazepine either before (i.e. (ii) and then (iii)) or after (i.e. (i) and then (ii)) introducing the desired leaving group. Steps (i)-(iii) are as described above in relation to Scheme 1.

$[^{18}\text{F}]$ Fluoride is typically obtained as an aqueous solution which is a product of the irradiation of an $[^{18}\text{O}]$ -water target. It has been widespread practice to carry out various steps in order to convert $[^{18}\text{F}]$ Fluoride into a reactive nucleophilic reagent, such that it is suitable for use in nucleophilic radiolabelling reactions. These steps include the elimination of water from $[^{18}\text{F}]$ -fluoride ion and the provision of a suitable counterion (*Handbook of Radiopharmaceuticals* 2003 Welch & Redvanly eds. ch. 6 pp 195-227). Nucleophilic radiofluorination reactions are then carried out using anhydrous solvents (Aigbirhio *et al* 1995 *J Fluor Chem*; 70: 279-87). In order to increase the reactivity of fluoride and to avoid hydroxylated by-products resulting from the presence of water, water is typically removed from $[^{18}\text{F}]$ Fluoride prior to the reaction and the radiofluorination reactions are carried out using anhydrous reaction solvents (Aigbirhio *et al* 1995 *J Fluor Chem*; 70: 279-87). The removal of water from the $[^{18}\text{F}]$ Fluoride is referred to as making “naked” $[^{18}\text{F}]$ Fluoride. This is regarded in the prior art relating to nucleophilic fluoridation as a step necessary to increase the reactivity of fluoride as well as to avoid

hydroxylated by-products resulting from the presence of water (Moughamir *et al* 1998 Tett Letts; 39: 7305-6).

A further step that is used to improve the reactivity of [¹⁸F]Fluoride for radiofluoridation reactions is to add a cationic counterion prior to the removal of
5 water. The counterion should possess sufficient solubility within the anhydrous reaction solvent to maintain the solubility of the fluoride ion. Counterions that have been used include large but soft metal ions such as rubidium or caesium, potassium complexed with a cryptand such as KryptofixTM, or tetraalkylammonium salts. A preferred suitable source of [¹⁸F]Fluoride for use in the method of the
10 invention is selected from [¹⁸F] potassium fluoride and [¹⁸F] caesium fluoride. [¹⁸F] potassium fluoride is most preferred, and especially preferably when it is complexed with a cryptand such as KryptofixTM because of its good solubility in anhydrous solvents and enhanced fluoride reactivity.

In a preferred embodiment, the method of the invention may further comprise:

- 15 (iii) removal of excess [¹⁸F]Fluoride; and/or,
(iv) removal of any protecting groups; and/or,
(v) removal of organic solvent; and/or,
(vi) formulation of the resultant compound together with a biocompatible carrier
to obtain a radiopharmaceutical composition suitable for mammalian
20 administration.

The "biocompatible carrier" is a fluid, especially a liquid, in which the radiofluorinated compound is suspended or dissolved, such that the radiopharmaceutical composition is physiologically tolerable, i.e. can be administered to the mammalian body without toxicity or undue discomfort. The
25 biocompatible carrier is suitably an injectable carrier liquid such as sterile, pyrogen-free water for injection; an aqueous solution such as saline (which may advantageously be balanced so that the final product for injection is either isotonic or not hypotonic); an aqueous solution of one or more tonicity-adjusting

substances (e.g. salts of plasma cations with biocompatible counterions), sugars (e.g. glucose or sucrose), sugar alcohols (e.g. sorbitol or mannitol), glycols (e.g. glycerol), or other non-ionic polyol materials (e.g. polyethyleneglycols, propylene glycols and the like). The biocompatible carrier may also comprise biocompatible
5 organic solvents such as ethanol. Such organic solvents are useful to solubilise more lipophilic compounds or formulations. Preferably the biocompatible carrier is pyrogen-free water for injection, isotonic saline or an aqueous ethanol solution. The pH of the biocompatible carrier for intravenous injection is suitably in the range 4.0 to 10.5.

10 Currently, the synthesis of ^{18}F -labelled compounds, particularly for use as PET tracers, is most conveniently carried out by means of an automated synthesis apparatus, e.g. TracerlabTM and FastlabTM (both GE Healthcare). However, the prior art method is not suitable for automation. In Comparative Example 1
15 herein it is demonstrated that radiofluorination of nitromazenil is not an ideal approach for the automated synthesis of [^{18}F]FMZ on Fastlab due to the low yield, and also because of the temperature required to obtain effective incorporation of [^{18}F]fluoride. The existing FASTlab reaction vessel is made of a cyclo-olefin co-polymer (COC) which can be used at temperatures up to
20 130°C. The prior art method used to prepare [^{18}F]FMZ from a nitro precursor requires a temperatures of around 160°C. At these temperatures the COC reaction vessel loses containment.

As demonstrated in the experimental examples below, changing the leaving group on the nitromazenil precursor from nitro to trimethylammonium allowed the reaction temperature to be reduced to 130°C whilst maintaining an EOS
25 yield of 7%. Moving the nitro leaving group from the position *meta* to the amide carbonyl to the position *ortho* to the amide carbonyl gave an improvement in EOS yield from 2.7-7.7% to 18-23% whilst also reducing the reaction temperature.

In a particularly preferred embodiment, the method of the invention is
30 automated. The radiochemistry is performed on the automated synthesis

apparatus by fitting a "cassette" to the apparatus. Such a cassette normally includes fluid pathways, a reaction vessel, and ports for receiving reagent vials as well as any solid-phase extraction cartridges used in post-radiosynthetic clean up steps.

- 5 In a further aspect of the present invention there is provided a cassette for carrying out the automated method of the invention comprising:
- (i) a vessel containing a precursor compound, wherein said precursor compound is as suitably and preferably defined above; and
 - (ii) means for eluting the vessel with a suitable source of [¹⁸F]Fluoride,
10 wherein said suitable source of [¹⁸F]Fluoride is as suitably and preferably defined above.

The cassette may also comprise an ion-exchange cartridge for removal of excess ¹⁸F. The reagents, solvents and other consumables required for the automated synthesis may also be included together with a data medium, such
15 as a compact disc carrying software, which allows the automated synthesiser to be operated in a way to meet the end user's requirements for concentration, volumes, time of delivery etc.

In another aspect, the present invention provides a compound of Formula I as defined in the method of the invention wherein R¹ is hydrogen, R² is [¹⁸F], and R⁴
20 is ethyl, isopropyl or *t*-butyl, wherein R⁴ is most preferably ethyl.

In a yet further aspect, the present invention provides a precursor compound of Formula Ia is as defined above wherein one of R¹¹ and R¹² is trimethylammonium or -I⁺-Ar, and the other is hydrogen. Preferably, one of R¹¹ and R¹² is trimethylammonium and the other is hydrogen. Most preferably, R¹² is nitro,
25 trimethylammonium or -I⁺-Ar, most especially preferably R¹² is nitro. R¹³ is preferably C(=O)-O-R⁴ wherein R⁴ is ethyl, isopropyl or *tert*-butyl, and wherein R⁴ is preferably ethyl.

Brief Description of the Examples

Comparative Example 1 describes the preparation of [¹⁸F]flumazenil from a nitro precursor compound.

5 Example 2 describes the preparation of [¹⁸F]flumazenil from a trimethylammonium precursor compound.

Example 3 describes the preparation of an iodonium salt precursor compound for [¹⁸F]flumazenil.

Example 4 describes the preparation of ortho-[¹⁸F]flumazenil from a nitro precursor compound.

10 Example 5 describes the preparation of ortho-[¹⁸F]flumazenil tert-butyl ester from a nitro precursor compound.


Example 6 describes the preparation of ortho-[¹⁸F]flumazenil isopropyl ester from a nitro precursor compound.

15 Example 7 describes a method for evaluation of the *in vivo* biodistribution of ortho-[¹⁸F]flumazenil.

List of Abbreviations used in the Examples

aq	aqueous
CIP	2-Chloro-1,3-dimethylimidazolidium hexafluorophosphate
DCM	dichloromethane
20 DIPEA	N,N-Diisopropylethylamine
DMF	dimethyl formamide
DMSO	dimethyl sulfoxide
EOS	end of synthesis


	Et	ethyl
	g	gram(s)
	h	hour(s)
	HPLC	high performance liquid chromatography
5	LCMS	liquid chromatography mass spectrometry
	MeCN	acetonitrile
	min	minute(s)
	mL	millilitre(s)
	mM	millimolar
10	mmol	millimole(s)
	mol	mole(s)
	QMA	quaternary methylammonium
	Rf	retention factor
	rt	room temperature
15	SPE	solid phase extraction
	TBA	tetrabutylammonium
	TEA	triethanolamine
	THF	tetrahydrofuran
	TLC	thin layer chromatography
20	UV	ultraviolet

Examples**Comparative Example 1: Preparation of [¹⁸F]flumazenil ([¹⁸F]FMZ) from Nitromazenil****Example 1(i): Synthesis of 4-Methyl-7-nitro-3,4-dihydro-1H-****benzo[e][1,4]diazepine-2,5-dione (1)****1**

- Commercially-available 5-Nitroisatoic anhydride (40 g, 0.192 mol) was dissolved in DMSO (50 mL) by stirring and heating the flask slowly to 140°C. Sarcosine (17.1 g, 0.192 mol) was slowly added in portions to the solution.
- 10 Upon addition, at 140°C, the solution started bubbling (generation of CO₂). The mixture was left stirring for 2.5 h. The mixture was left to cool and slowly poured on ice cold water in a beaker. The solution was stirred with a glass rod and a yellow solid precipitated out. The solid was separated by filtration and washed several time with water, then dried in vacuum oven at 40°C overnight.
- 15 The yellow solid isolated was identified as the desired product **1** in a 78% yield.

¹H NMR (D₆-DMSO): δ 3.14 (3H, s, NCH₃), 3.97 (2H, s, NCH₂CO), 7.30 (1H, d, J = 9 Hz, HNCCHCH), 8.33 (1H, dd, J = 9 and 3 Hz, CHCHCNO₂CH), 8.33 (1H, d, J = 3 Hz, OC-CCH), 11.05 (1H, s, NH).

20

Example 1(ii): Preparation of Nitromazenil (2)

Potassium *tert*-butoxide (0.6 g, 5 mmol) was added to a solution of intermediate **1** (1 g, 4.3 mmol) in THF (10 mL) and DMF (2 mL) at 0°C under nitrogen. After 30 min the reaction was cooled to 0°C, treated dropwise with diethyl chlorophosphate (0.7 mL, 5 mmol) and stirred for 30 min. Meanwhile to a stirred solution of ethyl isocyanoacetate (0.6 mL, 5 mmol) in THF (10 mL) under nitrogen at 0°C was added potassium *tert*-butoxide (0.6 g, 5 mmol) and stirred for 15 min. This was then added slowly to the mixture of intermediate **1** at 0°C. This was stirred at 0°C for 0.5 h then at room temperature for another 2 h. TLC (ethyl acetate) showed starting material (R_f 0.4) and a new spot (R_f 0.2) by UV and KMnO₄.

The reaction was quenched with acetic acid and left stirring overnight. The reaction mixture was poured into ice/water. This was extracted with ethyl acetate, and the organic layer was washed with water, brine, dried and concentrated to a thick dark dense oil. This was chromatographed on several times using the following conditions:


1) Companion, using DCM/ethyl acetate (twice)

2) Companion using petrol/ethyl acetate (twice)

50 mg of the pure material **2** was obtained as a colourless solid (yield 4%)

¹H NMR (CDCl₃): δ 1.39 (3H, *t*, *J* = 7 Hz, CH₃), 3.28 (3H, *s*, ArCONCH₃), 4.37 (2H, *q*, *J* = 7 Hz, OCH₂), 4.40 (1H, *br s*, CH₂), 5.26 (1H, *br s*, CH₂), 7.60 (1H, *d*, *J* = 8.9 Hz, ArCHCHCNO₂), 7.94 (1H, *s*, NCHN), 8.45 (1H, *dd*, *J* = 8.9 and 2.8 Hz, ArCHCHCNO₂), 8.95 (1H, *d*, *J* = 2.5 Hz, ArCHCNO₂).

Example 1(iii): Radiofluorination of Nitromazenil (2) to Obtain [¹⁸F] flumazenil ([¹⁸F]FMZ)



- ¹⁸F labeling was done on a TRACERlab automated synthesis module (GE Healthcare). [¹⁸F] fluoride was trapped on a pre-conditioned QMA cartridge and then transferred to the reaction vessel using a solution of tetra-n-butylammonium bicarbonate in MeCN/water (MeCN 1400 μL, water 100 μL, TBA.HCO₃ 27 mg) from vial 1. The solution was dried at 100°C for 10 minutes then 120°C for 20 minutes using nitrogen plus vacuum flow and then cooled to 50°C.
- 10 To the dried [¹⁸F]fluoride was added nitromazenil (18.8 mg) in DMF (1 mL) from vial 3. The reaction mixture was heated at 160°C for 30 min then it was cooled to 50°C. The reaction mixture was diluted with 10 mM phosphoric acid (2.5 mL) from vial 5 and was transferred to the crude product tube.

- The crude product was then transferred onto the preparative HPLC loop manually.
- 15 Preparative HPLC gave a peak with retention time 17.5 minutes which was cut using into the TRACERlab round bottomed flask containing water (12 mL). The preparative HPLC system was fitted with a liquid flow scintillation counter.

HPLC Column	Phenomenex Luna C18(2) 250x10mm 5 μ
Solvent	A = 10 mM phosphoric acid, B = MeCN, 25% B isocratic
Flow rate	4 mL/min
UV	254 nm
Loop	5 mL
Sensitivity	2000K

The mixture in the round bottom flask was trapped on a tC18 plus lite SPE


cartridge (pre conditioned with 1 mL ethanol then 2 mL water). The SPE cartridge was washed with water (3 mL) and the crude product eluted into a P6 vial using EtOH (0.5 mL) and water (4.5 mL).

Initial activity	193.8 MBq	@11:14
Activity of formulated product	14.8 MBq	@12:48

=7.7% end of synthesis yield


5 **Example 2: Preparation of [¹⁸F]flumazenil ([¹⁸F]FMZ) from a Trimethylammonium Precursor Compound**

Example 2(i): Synthesis of 4-methyl-7-Amino-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione (3)



- 10 Intermediate **1** (3.48 g, 15 mmol, preparation described in Example 1) was suspended in a 120 mL of 1:1 solution of THF/Ethanol. The suspension was treated with nitrogen followed by vacuum, before adding Pd/C 10% (0.7 g), suspended in ethanol. The reaction vessel was then fitted onto the Parr hydrogenator and left under hydrogen pressure (20 psi) for about 3 hours with
- 15 stirring. The excess hydrogen gas was removed using vacuum and then nitrogen was purged through the solution. The catalyst was filtered off using celite and the filtrate was evaporated to the minimum amount of ethanol. A white precipitate formed which was separated by filtration and dried under vacuum to afford 918 mg of desired material **3** in 30% yield.
- 20 ¹H NMR (DMSO): δ 3.07 (3H, s, NCH₃), 3.74 (2H, s, NCH₂CO), 5.19 (2H, s, NH₂), 6.69 (1H, dd, J = 8.6 and 2.5 Hz, ArCHCNH₂), 6.77 (1H, d, J = 8.6 Hz, ArCHCNHCO), 6.90 (1H, d, J = 2.5 Hz, COCCHCNH₂), 9.97 (1H, s, NH).

Example 2(iii): Synthesis of 4-methyl-7-Dimethylamino-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione (4)



To a solution of intermediate **3** (3.0 g, 13 mmol) and 37% aq formaldehyde (21
5 mL, 0.26 mol) in acetonitrile at 0°C, NaBH₃CN (4.8 g, 77 mmol) was added
portionwise. The reaction mixture was stirred at 0°C for 2 h and then at room
temperature for 1 h. Acetic acid (1.4 mL) was then added and the reaction
mixture was stirred for another 2 h. The reaction mixture was poured into ethyl
ether, washed with 2N KOH and the basic layer was extracted several times
10 with ethyl acetate. The organic phases were collected and dried and solvents
removed in vacuum to give an amorphous yellowish solid.


Notes: upon addition of acetic acid formation of gas was observed and the
reaction was strongly exothermic.

The solid obtained was triturated with ethyl acetate, isolated by filtration and
15 washed with diethyl ether to give a pale yellow fluffy solid. Proton NMR
confirmed the material to be intermediate **4** (2.97 g, 98%).

¹H NMR (DMSO): δ 3.09 (3H, s, NCH₃), 3.77 (2H, s, NCH₂CO), 6.92-6.98 (3H,
m, ArCHCN(CH₃)₂, ArCHCNHCO, COCCHCN(CH₃)₂), 10.09 (1H, s, NH).


20

Example 2(iii): Synthesis of Trimethyl-(4-methyl-2,5-dioxo-2,3,4,5-tetrahydro-

1H-benzo[e][1,4]diazepin-7-yl)-ammonium (5)

Intermediate **4** (2.97 g, 13 mmol) was dissolved in DCM (75 mL) and methyl triflate (1.67 mL, 15 mmol) was added at room temperature dropwise under nitrogen flow. Within 1 min a solid started to crash out of solution. After 10 min TLC analysis (ethyl acetate) showed that SM had disappeared. The reaction was therefore stopped. Diethyl ether (20 mL) was added and the solid was isolated by filtration as white sticky material. The reaction afforded intermediate **5** in quantitative yield.

¹H NMR (DMSO): δ 3.15 (3H, s, CONCH₃), 3.61 (9H, s, N⁺(CH₃)₃), 3.91 (2H, s, NCH₂CO), 7.28 (1H, d, J = 9.19 Hz, ArCHCNHCO), 8.10 (1H, dd, J = 3.06 and 9.19 Hz, ArCHCN⁺(CH₃)₃), 8.25 (1H, d, J = 3.06 Hz, COCCHCN⁺(CH₃)₃), 10.73 (1H, s, NH).

Example 2(iv): Synthesis of the Trimethylammonium Precursor Compound (6)


Sodium hydride (240 mg of a 60% dispersion in mineral oil, 6 mmol) was added to a solution of intermediate **5** (2 g, 5 mmol) in THF (15 mL) and DMF (10 mL) at room temperature under nitrogen. After 40 min the reaction was cooled to 0°C and treated dropwise with diethyl chlorophosphate (1.08 mL, 7.5 mmol) and stirred for 30 min. Meanwhile to a stirred solution of ethyl isocynoacetate (0.656 mL, 6 mmol) in DMF (6 mL) under nitrogen at 0°C was added sodium hydride (280 mg of a 60% dispersion in mineral oil, 7 mmol) and stirred for 15

min. This was then added slowly to the mixture of intermediate **5** at 0°C. This was stirred at 0°C for 0.5 h then room temperature for 30 mins. LCMS analysis of the crude after this time showed presence of desired mass. The reaction was quenched with acetic acid and worked up.

- 5 The reaction mixture was poured into ice/water. This was extracted with ethyl acetate, followed by DCM. LCMS analysis of the organics and the water suggested desired material present in the water layer. This was therefore taken to dryness (using rotary evaporation) and then the crude analysed by semiprep HPLC. The desired product **6** was isolated in 25% yield.
- 10 HPLC conditions: 5-95% methanol/water gradient over 30 mins; Luna 10 μ m C18(2) 250 x 50 mm column.

- ¹H NMR (D₂O): δ 1.37 (3H, *t*, *J* = 7.1 Hz, COOCH₂CH₃), 3.22 (3H, *s*, NCH₃), 3.73 (9H, *s*, N(CH₃)₃), 4.41 (2H, *m*, COOCH₂CH₃), 4. (1H, *br d*, *J* = 15.3 Hz, NCH₂), 5.13 (1H, *br d*, *J* = 15.3 Hz, NCH₂), 7.93 (1H, *d*, *J* = 9.2 Hz, ArCHCNHCO), 8.25 (1H, *dd*, *J* = 9.2 and 3.1 Hz, ArCHCN⁺(CH₃)₃), 8.27 (1H, *s*, ArNCHN), 8.40 (1H, *d*, *J* = 3.1 Hz, COCCHCN⁺(CH₃)₃).
- 15

Example 2(v): Radiofluorination of Trimethylammonium Precursor Compound (6) to Obtain [¹⁸F]flumazenil([¹⁸F]FMZ)




- 20 [¹⁸F] fluoride was transferred to a Wheaton vial to which was added TBA.HCO₃ (400 μ L). The solution was dried at 110°C under a flow of N₂ (~0.5L/ min) for 30 min, then cooled to room temperature.

To the dried [¹⁸F] fluoride was added the trimethylammonium precursor (31 mg) in DMSO (1mL). The reaction mixture was heated at 130°C for 25 min when it

was cooled to room temperature. The reaction mixture was transferred from the Wheaton vial into a P6 vial. The Wheaton vial was rinsed with water (1mL) and transferred to the P6 vial, an additional 3mL of ammonium acetate (50mM) was added. The reaction mixture was loaded onto preparative HPLC (Hichrom ACE C5 10x100mm column; solvent A = 50mM Ammonium Acetate, solvent B = MeCN; 4mL/min; UV 254nm) for purification.

Analytical HPLC (Phenomenex Luna C18(2) 50x2mm column; solvent A = 50mM Ammonium Acetate, solvent B = MeCN; 0.4mL/min; UV 254nm) confirmed that [¹⁸F] flumazenil was obtained at 95% radiochemical purity. The end of synthesis yield of [¹⁸F]flumazenil using this method was 6%.


Example 3: Preparation of an Iodonium Salt Precursor Compound for [¹⁸F]flumazenil ([¹⁸F]FMZ)



Commercially available 5-bromoisoatoic anhydride (**7**) was heated in DMSO with sarcosine at 150°C. This afforded intermediate **8** in 75% yield. The annulation afforded intermediate **9** with a yield of 30% using the conditions illustrated in the reaction scheme. Intermediate **9** and hexamethylditin/Pd(PPh₃)₄ were heated in the microwave at 130°C for 15 minutes to afford the stannane intermediate **10** in 35% yield. The iodonium conversion was obtained using a 1:5 ratio of intermediate **10** and (diacetoxyiodo)benzene, after 24 h at RT the

reaction had gone to completion. The desired iodonium salt precursor compound **11** was obtained in 21% yield.

Example 4: Preparation of ortho-¹⁸F]flumazenil from ortho-Nitromazenil



5

Example 4(i) Preparation of 2-Fluoro-6-nitro benzoic acid Ethyl Ester (12**)**

2-Fluoro-6-nitro benzoic acid (1.5 g, 8 mmol) was suspended in DCM (30 mL) under nitrogen flow at 0°C. Oxalyl chloride (1.5 g, 1.06 mL, 12 mmol) was slowly added and the reaction was left stirring overnight. The formation of the acyl chloride could be followed by TLC (ethyl acetate). The solvent was removed *in vacuo* and the residue was redissolved in DCM (20 mL). Ethanol (0.4 g, 0.5 mL, 8 mmol) was added at 0°C with TEA (0.8 g, 1.1 mL, 8 mmol) and the reaction was left stirring at room temperature for 3 hours. After this time a small amount of mixture was analysed by ¹H & ¹⁹F NMR to show

quantitative formation of **12**.

The reaction mixture was diluted with DCM (20 mL) and washed with water (2 x 50mL). The organic layer was separated, dried over MgSO₄ and filtered. The solvent was removed to dryness to afford a brown oil, which gave white
5 crystals of **12** (1.5 g, 88 %) over time.

¹H NMR (300 MHz, CDCl₃): δ_H 1.39 (3H, *t*, *J* = 7.1 Hz, COOCH₂CH₃), 4.47 (2H, *q*, *J* = 7.1 Hz, COOCH₂CH₃), 7.47 (1H, *td*, *J* = 8.3 and 1.2 Hz, NO₂CCHCH₂CHCF), 7.59 (1H, *td*, *J* = 8.3 and 5.2 Hz, NO₂CCHCH₂CHCF), 7.98 (1H, *dt*, *J* = 8.3 and 0.9 Hz, NO₂CCH₂CHCHCF); ¹⁹F NMR (282 MHz, CDCl₃): □_F
10 -112.4.

Example 4(ii) Preparation of Intermediate **13**

12 (3 g, 0.014 mol) and ethyl 4-methyl-5-imidazole-carboxylate (1.96 g, 0.013 mol) were dissolved in 30 mL of DMSO. Cesium carbonate (4.6 g, 0.014 mol) was added and the mixture was stirred at rt for 3 days.

15 Crude was analysed by LCMS using a 5-95% acetonitrile/water gradient over 3 min. This showed a new species with mass 348.03 in the positive.

TLC analysis (Ethyl acetate) showed a new spot with *r_f* 0.4.

The reaction mixture was poured into ice water and then extracted with ethyl acetate (x1) followed by DCM (x3). The combined organics were concentrated
20 and liquid loaded on silica column for flash chromatography (details on next page). The product **13** was isolated in 72% yield (3.5 g).

¹H NMR (CDCl₃): δ 1.19 (6H, *t*, *J* = 7.05 Hz, COOCH₂CH₃), 1.42 (3H, *t*, *J* = 7.05 Hz, COOCH₂CH₃), 2.37 (3H, *s*, NCCH₃), 4.21 (2H, *q*, *J* = 7.05 Hz, COOCH₂CH₃), 4.41 (2H, *q*, *J* = 7.05 Hz, COOCH₂CH₃), 7.49 (1H, *s*, NCHN),
25 7.62 (1H, *dd*, *J* = 7.97 Hz, CCH₂CHCHCNO₂), 7.77 (1H, *t*, *J* = 7.97 & 8.27 Hz, CCH₂CHCHCNO₂), 8.37 (1H, *dd*, *J* = 8.27 Hz, CCH₂CHCHCNO₂).

Example 4(iii) Preparation of ortho-Nitromazenil (14)

To a stirred solution of bromide (4.25g, 0.010 mol) in 50 mL of methanol a solution of DIPEA (2.84g, 3.8 mL, 0.022 mol) and methyl amine (6.5 mL of 2M solution in methanol, 0.013 mol) in methanol (50 mL) was slowly added. The
5 reaction was refluxed overnight. TLC analysis using ethyl acetate showed quantitative conversion of the starting material **13** to two main new spots (rf 0.5 and 0.3). Crude was analysed by LCMS using a 5-95% acetonitrile/water gradient over 3 min. This showed a new species with mass 331.03 in the positive and two other major peaks. The solvent was removed to dryness and
10 the crude was liquid loaded on column for flash chromatography using DCM/Ethyl acetate 1% methanol. LCMS of the 2 major combined fractions showed the desired material in a mixture with two other products.

Each fraction was submitted to a second purification using DCM/ethyl acetate. The product **14** was then re-crystallised from both fractions using ethanol.
15 Desired material was isolated pure in 15% yield.

^1H NMR (CDCl_3) δ 1.43 (3H, s, CH_3), 3.20 (3H, s, NCH_3), 4.32-4.50 (2H, m, OCH_2), 4.54 (1H, d, $J = 16$ Hz, NCH), 5.30 (1H, d, $J = 16$ Hz, NCH'), 7.66 (1H, dd, $J = 8$ Hz and 1 Hz, NCCH), 7.70 (1H, dd, $J = 8$ and 8 Hz, CHCHCH), 7.94 (1H, dd, $J = 8$ and 1 Hz, CHCNO_2), 7.97 (1H, s, NCHN).

20 Example 4(iv): Radiofluorination of ortho-Nitromazenil to Obtain ortho- ^{18}F flumazenil

Radiofluorination was done on a FASTlab automated synthesis module (GE Healthcare).

A cassette was assembled from component parts as follows. An 11mm vial
25 containing 20.5 mg K222, 140 μl K_2CO_3 (2.9 mg in water) & 1.06 ml MeCN, a second 11mm vial containing 1.3 ml of precursor solution (6.5 mg precursor **14** in 1.3 ml of dry DMF), a 13 mm vial containing phosphoric acid (2.6 mL, 10 mM), a 13 mm vial containing saline (0.9%, 2.4 mL) and a 13mm vial

containing ethanol (4 mL) were inserted into the cassette. A pre-treated QMA cartridge was fitted, and a tC18+ cartridge.

The required operating sequence file was uploaded from the control PC into the internal memory of the FASTlab. The cassette was mounted on to the FASTlab synthesizer. The [¹⁸F]fluoride vial was pierced using a needle
 5 connected to the line to the fluoride inlet on the FASTlab. A clean, empty product collection vial was connected which was pre filled with 0.9% saline (7 mL). The synthesis sequence was then commenced and the FASTlab hardware test step completed. The fluoride was trapped on the QMA cartridge
 10 and dried in the reaction vessel. The solution of precursor **14** was added and heated at 130°C for 30 minutes. The reaction mixture was diluted with phosphoric acid (10 mM, 2.2 mL). Once the crude product had transferred to the HPLC loop, the HPLC run was started (see below for details of the preparative HPLC conditions).

HPLC Column	Phenomenex Prodigy ODS-prep 250x10mm 10 μ
Solvent	A = 10 mM phosphoric acid, B = MeCN, 25% B isocratic
Flow rate	4 mL/min
UV	254 nm
Loop	5 mL
Sensitivity	200K

15

Once the product had been injected onto the prep HPLC the cut (retention time 13.7 minutes) was performed manually for approximately 1 minute into a vial containing ~13 ml water. The diluted cut was drawn back onto the FASTlab for reformulation on the tC18 plus cartridge. The amount of radioactivity in
 20 formulated product (in 1 mL ethanol and 9 mL saline) was measured in an ion chamber. A sample of product was sub dispensed and posted out of the hot cell for analysis.

Initial activity	21100 MBq	@12:00
Activity of formulated product	4880 MBq	@13:28
=23% end of synthesis yield		

Radiochemical purity was >99% two hours after the end of synthesis.


Total cold ligand measured by was 3 µg/10 mL volume. This is calculated using analytical HPLC UV peak area with the cold reference compound as
5 calibrating standard.

This automated synthesis method produced radiolabeled material with approximately 1 µg of cold impurities total. This automated process also gave consistent yields over a range of starting radioactivity levels. The results from four consecutive syntheses are shown below.

Non decay corrected EOS yield	Amount of formulated product (MBq)	Radiochemical purity	Amount of cold ligand µg	Amount of impurities µg
18.22	72.7	>99		
23.13	4880	>99		
20.34	7220	>99		
21.59	38	>99	0.6	~ 1.0

10

Example 5: Preparation of ortho-¹⁸F]flumazenil tert-butyl ester from ortho-Nitromazenil tert-butyl ester (17)



Example 5(i): Preparation of Nitro Isatoic Acid (15)

- 5 2,6-Dinitrobenzoic acid (0.5 g, 2.36 mmol) in ethanol (5 mL) was heated to 80°C. Ammonium sulfide (40-48% in water) (0.36 mL, 2.36 mmol) was then added (the yellow solution became a bright orange suspension) the mixture was heated under reflux for 0.5 h. TLC (DCM 80%, MeOH 20%) showed a faint spot below the starting material. Ammonium sulfide (3.6 mL, 20.4 mmol) was added and the
- 10 mixture became a darker orange. This mixture was then heated under reflux for 1 h after which time TLC indicated that the reaction had gone to completion. The solvents were removed under reduced pressure and then the residue washed with methanol. The methanol solution was decanted off and evaporated to dryness to afford 2-nitro-6-amino benzoic acid as a orange solid. This was then purified
- 15 using flash chromatography (DCM 90%/MeOH 10% -> 20% MeOH over 60CV, 12 g column) to afford the desired material (0.2 g, 46%).

¹H NMR (D₆-DMSO) δ 3.16 (2H, s, NH₂), 6.80 (1H, dd, J = 8 and 1 Hz, H₂NCCH), 6.93 (1H, dd, J = 8 and 1 Hz, CHCNO₂), 7.22 (1H, dd, J = 8 and 8 Hz, CHCHCH).

2-nitro-6-amino benzoic acid (2.8 g, 15.4 mmol) was dissolved in dioxane (20 mL).

Triphosgene (1.52 g, 5.1 mmol) was added. The mixture was then heated under reflux for 1 h. The mixture was then allowed to cool. The precipitate was then collected by filtration to give the isatoic anhydride in quantitative yield.

¹H NMR (D₆-DMSO) δ 7.33 (1H, *dd*, *J* = 8 and 1 Hz, ArCH), 7.59 (1H, *dd*, *J* = 8 and 1 Hz, ArCH), 7.89 (1H, *dd*, *J* = 8 Hz, ArCH), 12.2 (1H, *br s*, NH).

Example 5(ii): Preparation of 4-Methyl-6-nitro-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione (16)

Nitro isatoic acid (**15**) (3.5 g, 16.8 mmol) and sarcosine (1.50 g, 16.8 mmol) was dissolved in DMSO (8 mL). The mixture was then placed in a preheated heating mantle at 150°C. The mixture was then heated at this temperature for *ca.* 30 minutes; after which time the reaction mixture was poured into water (50 mL). The resulting brown precipitate was collected by filtration and triturated with ethyl acetate to afford a pale brown powder (0.9 g, 11%).

¹H NMR (300 MHz, DMSO-d₆): δ_H 3.08 (3H, *s*, NCH₃), 4.16 (2H, *br s*, CH₂), 7.39 (1H, *dd*, *J* = 8.0 and 2.0 Hz, HNCCH), 7.66 (1H, *dd*, *J* = 8.0 and 8.0 Hz, CHCHCH), 7.72 (1H, *dd*, *J* = 8.0 and 2.0 Hz, CHCNO₂), and 10.80 (1H, *br s*, NH); ¹³C NMR (300 MHz, DMSO-d₆): δ_C 34.9 (NCH₃), 51.8 (NCH₂), 119.9 (CHCHCNH), 121.0 (C-CO), 125.1 (CHCHCNO₂), 138.3 (CNH), 151.0 (C-NO₂), 163.2 (C=O), and 169.7 (C=O).

Example 5(iii): Preparation of ortho-Nitromazenil tert-butyl ester (17)

Potassium *tert*-butoxide (0.37 g, 3.27 mmol) was added to intermediate **16** (0.7 g, 2.98 mmol) in THF (56 mL) at 0°C. The mixture was then stirred at 0°C for 20 min (during which time a bright yellow precipitate was observed) and then cooled to -35°C. Diethyl chlorophosphate (0.67 g, 3.88 mmol, 0.56 mL) was added slowly. The reaction was stirred at 0°C for 30 min during which time mixture became slightly more yellow in colour. The reaction flask was cooled to -35°C and solution of *tert*-butyl isocynoacetate (0.46 g, 3.26 mmol, 0.48 mL) was added followed by potassium *tert*-butoxide (0.37 g, 3.27 mmol). The suspension was then left to stir

at room temperature overnight. The reaction was quenched with aq NaHCO₃ (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic layers were dried over MgSO₄, concentrated to afford brown oil. The crude material was purified by silica gel chromatography eluting with ethyl acetate (A): methanol (B) (0-1% B, 100 g, 40 mL/min). **17** was obtained as a pale yellow solid (9 mg, 1%).

¹H NMR (300 MHz, CDCl₃): δ_H 1.64 (9H, s, C(CH₃)₃), 3.19 (3H, s, NCH₃), 4.52 (1H, d, J = 15.0 Hz, CONCH₃CH_aH_b), 5.45 (1H, d, J = 15 Hz, CONCH₃CH_aH_b), 7.64 (1H, dd, J = 9.0 and 3.0 Hz, NCCH₂CH), 7.73 (1H, dd, J = 9.0 and 9.0 Hz, NCCH₂CH), 7.93 (1H, dd, J = 9.0 and 3.0 Hz, O₂NCCH₂CH), and 7.94 (1H, s, NCH₃).

Example 5(iv): Radiofluorination of ortho-Nitromazenil tert-butyl ester (**17**) to Obtain ortho-[¹⁸F]flumazenil tert-butyl ester

Radiofluorination was done on a TRACERlab automated synthesis module (GE Healthcare). The [¹⁸F] fluoride was trapped on a pre-conditioned QMA cartridge and then transferred to the reaction vessel using a solution of Kryptofix 2.2.2 (11 mg) in MeCN (2000 μL) and K₂CO₃ (in 80 μL water, 1.7 mg) from vial 1. The solution was dried at 100°C for 10 minutes then 120°C for 20 minutes using nitrogen plus vacuum flow and then cooled to 50°C.

To the dried [¹⁸F]fluoride was added ortho-nitromazenil tert-butyl ester (**17**, 5 mg) in DMF (1 mL) from vial 3. The reaction mixture was heated at 130°C for 30 min then it was cooled to 50°C. The reaction mixture was diluted with 10 mM phosphoric acid (2.5 mL) from vial 5 and was transferred to the crude product tube.

The crude product was then transferred onto the preparative HPLC loop manually. Preparative HPLC gave a peak with retention time 13.5 minutes which was cut into the TRACERlab round bottomed flask containing water (12 mL). The preparative HPLC system was fitted with a liquid flow scintillation counter.

HPLC Column	Phenomenex Prodigy ODS-prep 250x10mm 10 μ
Solvent	A = 10 mM phosphoric acid, B = MeCN, 30% B isocratic
Flow rate	4 mL/min
UV	254 nm
Loop	5 mL
Sensitivity	2000K

The mixture in the round bottom flask was trapped on a C18 lite SPE (pre conditioned with 1 mL ethanol then 2 mL water). The SPE was washed with water (3 mL) and the crude product eluted into a P6 vial using EtOH (0.5 mL) and phosphate buffered saline (4.5 mL). The product was further diluted using phosphate buffered saline to give a final volume of 10 mL.


Initial activity	828 MBq	@9:59
Activity of formulated product	121 MBq	@11:51

=14.6% end of synthesis yield

Radiochemical purity was >99% two hours after the end of synthesis.

Total cold ligand measured by was 6 μ g/10 mL volume (calculated using analytical HPLC UV peak area with the cold reference compound as calibrating standard).

Example 6: Radiofluorination of ortho-Nitromazenil isopropyl ester (18) to Obtain ortho-[¹⁸F]flumazenil isopropyl ester



Example 6(i): Preparation of ortho-Nitromazenil isopropyl ester (18)

5 **14** (preparation described in Example 4(iii); 20 mg, 0.06 mmol) was dissolved in 2 mL of isopropanol in a microwave vessel and 50 μ L of Titanium (IV) isopropoxide were added. Microwave conditions: Temperature: 85°C; Time: 60 mins. LCMS confirmed quantitative conversion of the starting material to the desired product. This was also confirmed by TLC using ethyl acetate. The excess isopropanol was removed to dryness and the crude mixture was liquid loaded on column for flash chromatography using petrol and ethyl acetate as eluent. The material was purified again using DCM/Methanol. **18** (15 mg) was obtained pure (73%).

¹H NMR (CDCl₃) δ 1.43 (3H, *d*, *J* = 6.1 Hz, CH₃), 1.45 (3H, *d*, *J* = 6.1 Hz, CH₃), 3.20 (3H, *s*, NCH₃), 4.53 (1H, *d*, *J* = 16 Hz, CH), 5.28 (1H, *d*, *J* = 16 Hz, CH'), 5.33 (1H, *m*, COOCH(CH₃)₂), 7.66 (1H, *dd*, *J* = 0.92, 8.27 Hz, CHCHCHCNO₂), 7.75 (1H, *t*, *J* = 8.3 Hz, CHCHCHCNO₂), 7.94 (1H, *dd*, *J* = 0.92, 8.27 Hz, CHCHCHCNO₂), 7.97 (1H, *s*, NCHN).

Example 6(ii): Radiofluorination of ortho-Nitromazenil isopropyl ester (18) to Obtain ortho-[¹⁸F]flumazenil isopropyl ester

20 Radiofluorination was done on a TRACERlab automated synthesis module (GE Healthcare). The [¹⁸F] fluoride was trapped on a pre-conditioned QMA cartridge and then transferred to the reaction vessel using a solution of Kryptofix 2.2.2 (11 mg) in MeCN (2000 μ L) and K₂CO₃ (in 80 μ L water, 1.7 mg) from vial 1. The solution was dried at 100°C for 10 minutes then 120°C for 20 minutes using

nitrogen plus vacuum flow and then cooled to 50°C.

To the dried [¹⁸F]fluoride was added ortho-nitromazenil tert-butyl ester (2.5 mg) in DMF (1 mL) from vial 3. The reaction mixture was heated at 130°C for 30 min then it was cooled to 50°C. The reaction mixture was diluted with 10 mM phosphoric acid (2.5 mL) from vial 5 and was transferred to the crude product tube.

The crude product was then transferred onto the preparative HPLC loop manually. Preparative HPLC gave a peak with retention time 23 minutes which was cut into the TRACERlab round bottomed flask containing water (15 mL). The preparative HPLC system was fitted with a liquid flow scintillation counter.

HPLC Column	Phenomenex Prodigy ODS-prep 250x10mm 10 μ
Solvent	A = 10 mM phosphoric acid, B = MeCN, 25% B isocratic
Flow rate	4 mL/min
UV	254 nm
Loop	5 mL
Sensitivity	2000K

10

The mixture in the round bottom flask was trapped on a C18 lite SPE (pre conditioned with 1 mL ethanol then 2 mL water). The SPE was washed with water (3 mL) and the crude product eluted into a P6 vial using EtOH (0.8 mL) and phosphate buffered saline (7.2 mL).

15

Initial activity	800 MBq	@10:51
Activity of formulated product	114 MBq	@12:56

=14.2% end of synthesis yield

Radiochemical purity was >99% three hours after the end of synthesis.

Total cold ligand measured by was 2.4 µg/8 mL volume (calculated using analytical HPLC UV peak area with the cold reference compound as calibrating standard). Total cold impurities were approximately 2 µg.

Example 7: In Vivo Biodistribution of ortho-[¹⁸F]-flumazenil

- 5 Adult male Sprague-Dawley rats (body weight 202±37 g; mean ±SD) were injected with between 1 and 5 MBq of ortho-[¹⁸F]-flumazenil *via* a lateral tail vein. All animals were conscious, but lightly restrained during injection and subsequently housed in short-term metabolism cages. At the appropriate time point; 30 seconds, 2, 10, 30 and 60 minutes post-injection (pi) (n=3 per time
- 10 point), the animals were sacrificed by cervical dislocation. The brain and peripheral tissues or fluids were sampled post-mortem. Radioactivity in the brain samples was measured using a Wallac gamma counter. Once assayed, the brain samples, along with the remaining organ or tissue samples were
- 15 assayed using a twin-crystal gamma-counter system (BASIL), with automatic correction for radioactive decay. The table below shows the data obtained in the brain regions. Data is expressed as mean (±SD), and all are n=3. Data indicated by an asterisk (*) is % id/g.


Distribution of ortho-[¹⁸ F]-flumazenil					
Time Post-Injection [minutes (standard deviation)]					
	0.5	2	10	30	60
Brain Region (% id/g)					
Striatum	0.90 (0.02)	0.83 (0.22)	0.68 (0.08)	0.15 (0.02)	0.06 (0.03)
Cerebellum	0.99 (0.08)	1.01 (0.28)	0.96 (0.07)	0.38 (0.08)	0.11 (0.02)
Hippocampus	0.81 (0.04)	0.78 (0.25)	0.91 (0.06)	0.48 (0.10)	0.17 (0.01)
Pre-frontal cortex	1.12 (0.03)	1.14 (0.28)	1.39 (0.06)	0.76 (0.20)	0.29 (0.04)
Thalamus	1.03 (0.18)	0.85 (0.29)	0.94 (0.15)	0.33 (0.07)	0.08 (0.02)
Pituitary gland	0.98 (0.14)	1.12 (0.31)	0.46 (0.08)	0.15 (0.09)	0.02 (0.01)
Pons/Medulla	0.79 (0.03)	0.79 (0.22)	0.59 (0.05)	0.21 (0.15)	0.24 (0.38)
Pre-frontal cortex:thalamus	1.11	1.37	1.50	2.28	3.96

Initial uptake of radioactivity in the brain was $1.4 \pm 0.8\%$ id after 30 seconds pi, peaking at $1.8 \pm 0.5\%$ id at 2 minutes pi. After 2 minutes pi there was a steady decrease in radioactivity levels, with $0.9 \pm 0.2\%$ id after 30 minutes pi falling to
5 $0.3 \pm 0.1\%$ id by 60 minutes pi.

The region with the highest levels of radioactivity at the early time points was the pre-frontal cortex ($1.39 \pm 0.06\%$ id at 10 minutes pi). There was good differentiation between the GABA-rich and GABA-poor regions to 30 min pi.

Claims

1) A method to obtain a compound of Formula I:




wherein:

5 one of R¹ and R² is ¹⁸F and the other is hydrogen; and,

R³ is a C₃₋₅ heterocycle; or, R³ is C(=O)-O-R⁴ wherein R⁴ is hydrogen, or a straight- or branched-chain C₁₋₄ alkyl;

wherein said method comprises:

(i) providing a precursor compound of Formula Ia:



wherein:

one of R¹¹ and R¹² is a leaving group and the other is hydrogen, wherein:

when R¹¹ is said leaving group it is selected from tri-C₁₋₃ alkyl ammonium or -I⁺-Ar, wherein Ar is phenyl substituted with one or more R^{*} groups, wherein
 15 R^{*} is selected from hydrogen, nitro, cyano, halogen, C₁₋₁₀ hydroxyalkyl, C₂₋₁₀ carboxyalkyl, C₁₋₁₀ alkyl, C₂₋₁₀ alkoxyalkyl, C₁₋₁₀ hydroxyalkyl, C₁₋₁₀

aminoalkyl, C₁₋₁₀ haloalkyl, C₆₋₁₄ aryl, C₃₋₁₂ heteroaryl, C₃₋₂₀ alkylaryl, C₂₋₁₀ alkenyl, and C₂₋₁₀ alkynyl; and,

when R¹² is said leaving group it is selected from nitro, tri-C₁₋₃ alkyl ammonium or -I⁺-Ar, wherein Ar is as defined above for R¹¹; and,

5 R¹³ is as defined for R³ of Formula I; and,

(ii) reacting said precursor compound with a suitable source of [¹⁸F]Fluoride.

2) The method as defined in Claim 1 wherein R¹ is ¹⁸F.

3) The method as defined in Claim 2 wherein R¹¹ is trimethyl ammonium.

4) The method as defined in Claim 2 wherein R¹¹ is -I⁺-Ar.

10 5) The method as defined in Claim 1 wherein R² is ¹⁸F.

6) The method as defined in Claim 5 wherein R¹² is trimethyl ammonium.

7) The method as defined in Claim 5 wherein R¹² is -I⁺-Ar.

8) The method as defined in Claim 5 wherein R¹² is nitro.

9) The method as defined in any one of Claims 1-8 wherein R³ and R¹³ are
15 independently C(=O)-O-R⁴ wherein R⁴ is a straight- or branched-chain C₁₋₄
alkyl.

10)The method as defined in Claim 9 wherein R⁴ is ethyl, isopropyl or *tert*-butyl.

11)The method as defined in any one of Claims 1-10 wherein said suitable source
of [¹⁸F]Fluoride is selected from [¹⁸F] potassium fluoride and [¹⁸F] caesium
20 fluoride.

12)The method as defined in Claim 11 wherein said suitable source of
[¹⁸F]Fluoride is [¹⁸F] potassium fluoride and KryptofixTM is used to activate the
fluoride ion.

- 13)The method as defined in any one of Claims 1-12, which further comprises:
- (iii)removal of excess [¹⁸F]Fluoride; and/or,
 - (iv)removal of any protecting groups; and/or,
 - (v) removal of organic solvent; and/or,
 - 5 (vi)formulation of the resultant compound together with a biocompatible carrier to obtain a radiopharmaceutical composition suitable for mammalian administration.
- 14)The method as defined in any one of Claims 1-13 wherein said method is automated.
- 10 15)A cassette for carrying out the method as defined in Claim 14, wherein said cassette comprises:
- (i) a vessel containing a precursor compound, wherein said precursor compound is as defined in the method of any one of Claims 1, 3, 4, or 6-10; and
 - 15 (ii) means for eluting the vessel with a suitable source of [¹⁸F]Fluoride, wherein said suitable source of [¹⁸F]Fluoride is as defined in any one of Claims 1, 11 or 12.
- 16)The cassette as defined in Claim 15 which additionally comprises an ion-exchange cartridge for removal of excess [¹⁸F]Fluoride.
- 20 17)A compound of Formula I as defined in the method of Claim 1 wherein R¹ is hydrogen, R² is ¹⁸F, and R⁴ is ethyl, isopropyl or *tert*-butyl.
- 18)A precursor compound of Formula Ia as defined in the method of Claim 1 wherein one of R¹¹ and R¹² is trimethylammonium or -I⁺-Ar, and the other is hydrogen.
- 25 19)The precursor compound as defined in Claim 18 wherein one of R¹¹ and R¹² is

trimethylammonium and the other is hydrogen.

- 20) A precursor compound of Formula Ia as defined in the method of Claim 1 wherein R^{12} is nitro, trimethylammonium or $-I^+-Ar$.
- 21) The precursor compound as defined in Claim 20 wherein R^{12} is nitro.
- 5 22) The precursor compound as defined in any one of Claims 18-21 wherein R^{13} is $C(=O)-O-R^4$ wherein R^4 is ethyl, isopropyl or *tert*-butyl.

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2010/065077

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D487/04

ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>RYZHIKOV N N ET AL: "Preparation of highly specific radioactivity [^{18}F]flumazenil and its evaluation in cynomolgus monkey by positron emission tomography", NUCLEAR MEDICINE AND BIOLOGY, ELSEVIER, NY, US, vol. 32, no. 2, 1 February 2005 (2005-02-01), pages 109-116, XP004756707, ISSN: 0969-8051, DOI: DOI:10.1016/J.NUCMEDBIO.2004.11.001 cited in the application</p> <p>* abstract paragraphs [02.1], [3.1], [4.1]; figure 2; table 1</p> <p style="text-align: center;">----- -/--</p>	1-22



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

11 January 2011

Date of mailing of the international search report

20/01/2011

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Grassi, Damian

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2010/065077

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2005/097713 A1 (GE HEALTHCARE LTD [GB]; WADSWORTH HARRY JOHN [GB]; DEVENISH TONY [GB]) 20 October 2005 (2005-10-20)	1,2,4, 9-16,18, 22
Y	entry (n); page 10; claims 15-17	1-22
Y	----- MILLER PHILIP W ET AL: "Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography.", ANGEWANDTE CHEMIE, vol. 47, no. 47, 2008, pages 8998-9033, XP002609759, ISSN: 1521-3773 page 9015 - page 9017	1-22
X	EP 0 433 163 A2 (ROUSSEL UCLAF [FR]) 19 June 1991 (1991-06-19)	20,21
Y	page 9, lines 6,12 page 22	1-22

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2010/065077

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 2-4(completely); 1, 9-16, 18, 19, 22(partially)

Process for the preparation of compounds according to claim 1 in which R1 is 18F, the cassette according to claim 15 comprising a precursor of formula (Ia) in which R11 is the leaving group and the precursor according to claims 18, 19 and 22 in which R11 is the leaving group (this group is still not unitary because the special technical features trialkyl ammonium and -I+-Ar are not corresponding technical features).

2. claims: 5-8, 17, 20, 21(completely); 1, 9-16, 18, 19, 22(partially)

Process for the preparation of compounds according to claim 1 in which R2 is 18F, the cassette according to claim 15 comprising a precursor of formula (Ia) in which R12 is the leaving group, the compounds according to claims 17, 20, 21 and the precursor according to claims 18, 19 and 22 in which R12 is the leaving group.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2010/065077

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2005097713 A1	20-10-2005	CN 1938244 A	28-03-2007
		EP 1732865 A1	20-12-2006
		JP 2007532524 T	15-11-2007
		US 2007092441 A1	26-04-2007
EP 0433163 A2	19-06-1991	CA 2031898 A1	12-06-1991
		JP 4108789 A	09-04-1992